Tvardi Therapeutics (TVRD) Financials

Tvardi Therapeutics logo
$1.01 -0.09 (-8.18%)
Closing price 04:00 PM Eastern
Extended Trading
$1.05 +0.04 (+3.96%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Tvardi Therapeutics

Annual Income Statements for Tvardi Therapeutics

This table shows Tvardi Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-25 -57 -58 -74 -106 8.41 -88 -85 -119 -29 -18
Consolidated Net Income / (Loss)
-25 -57 -58 -74 -106 8.41 -88 -85 -119 -29 -18
Net Income / (Loss) Continuing Operations
-25 -57 -58 -74 -106 8.41 -88 -85 -119 -29 -18
Total Pre-Tax Income
-25 -58 -58 -74 -107 7.72 -89 -85 -119 -27 -25
Total Operating Income
-25 -58 -59 -77 -112 5.39 -89 -88 -121 -28 -27
Total Gross Profit
3.80 0.09 0.91 13 20 135 23 35 15 0.00 0.00
Total Revenue
3.80 0.09 0.91 13 20 135 23 42 21 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.27 6.17 0.00 0.00
Total Operating Expenses
29 58 60 91 132 130 112 122 136 28 27
Selling, General & Admin Expense
7.77 9.23 12 15 18 22 29 30 28 4.46 8.74
Research & Development Expense
21 49 49 76 114 108 83 92 109 24 18
Total Other Income / (Expense), net
0.10 0.65 1.16 2.98 4.49 2.33 0.00 2.06 2.98 0.75 1.38
Interest & Investment Income
- - - - - - - - - 0.75 1.38
Other Gains / (Losses), net
- - - - - - 0.64 0.00 0.00 -2.04 7.16
Basic Earnings per Share
($1.00) ($2.10) ($1.86) ($2.06) ($2.49) $0.18 ($1.74) ($19.12) ($26.26) ($11.42) ($2.46)
Weighted Average Basic Shares Outstanding
24.62M 27.28M 31.20M 35.89M 42.67M 47.41M 50.72M 4.47M 4.51M 2.57M 7.42M
Diluted Earnings per Share
($1.00) ($2.10) ($1.86) ($2.06) ($2.49) $0.18 ($1.74) ($19.12) ($26.26) ($11.42) ($3.26)
Weighted Average Diluted Shares Outstanding
24.62M 27.28M 31.20M 35.89M 42.67M 47.92M 50.72M 4.47M 4.51M 2.57M 7.78M
Weighted Average Basic & Diluted Shares Outstanding
24.62M 27.28M 31.20M 35.89M 42.67M 49.88M 53.51M 53.94M 54.66M 4.57M 9.38M
Cash Dividends to Common per Share
- - - - - - - - - - $0.00

Quarterly Income Statements for Tvardi Therapeutics

This table shows Tvardi Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-31 -6.98 -5.51 14 -9.58 4.17 -5.53 -12 -6.80 -6.46 -6.12
Consolidated Net Income / (Loss)
-31 -6.98 -5.51 14 -9.58 4.17 -5.53 -12 -6.80 -6.46 -6.12
Net Income / (Loss) Continuing Operations
-31 -6.98 -5.51 14 -9.58 4.17 -5.53 -12 -6.80 -6.46 -6.12
Total Pre-Tax Income
-31 -6.98 -5.51 16 -9.58 4.17 -5.53 -19 -6.80 -6.46 -6.12
Total Operating Income
-30 -7.18 -5.68 14 -4.35 -8.87 -5.94 -9.56 -7.05 -6.63 -6.33
Total Gross Profit
1.52 0.00 0.00 -1.52 0.00 0.00 0.00 -2.57 0.00 0.00 0.00
Total Revenue
2.14 0.00 0.00 -2.14 0.00 0.00 0.00 -2.57 0.00 0.00 0.00
Total Cost of Revenue
0.62 0.00 0.00 -0.62 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
31 7.18 5.68 -16 4.35 8.87 5.94 6.99 7.05 6.63 6.33
Selling, General & Admin Expense
6.82 0.65 0.88 -3.89 1.24 3.06 2.34 -1.30 2.14 2.63 1.85
Research & Development Expense
22 6.53 4.80 -9.64 3.11 5.81 3.60 8.28 4.91 4.00 4.47
Total Other Income / (Expense), net
-1.03 0.21 0.16 1.41 -5.23 13 0.41 -9.55 0.25 0.17 0.20
Interest & Investment Income
- 0.21 0.16 - 0.28 0.38 0.41 - 0.25 0.17 0.20
Other Gains / (Losses), net
- - 0.00 - - - - - - - 0.00
Basic Earnings per Share
($20.24) ($2.71) ($2.14) $5.36 ($3.72) $0.51 ($0.59) ($1.61) ($0.73) ($0.69) ($0.48)
Weighted Average Basic Shares Outstanding
1.52M 2.57M 2.57M 2.57M 2.58M 8.25M 9.38M 7.42M 9.38M 9.38M 12.65M
Diluted Earnings per Share
($20.24) ($2.71) ($2.14) $5.36 ($3.72) ($1.00) ($0.59) ($1.61) ($0.73) ($0.69) ($0.48)
Weighted Average Diluted Shares Outstanding
1.52M 2.57M 2.57M 2.57M 2.58M 8.46M 9.38M 7.78M 9.38M 9.38M 12.65M
Weighted Average Basic & Diluted Shares Outstanding
54.68M 54.85M 54.86M 4.57M 9.36M 9.38M 9.38M 9.38M 9.38M 13.34M 13.36M

Annual Cash Flow Statements for Tvardi Therapeutics

This table details how cash moves in and out of Tvardi Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-38 -2.24 -3.40 5.69 2.86 13 -18 50 -10 8.70 -11
Net Cash From Operating Activities
-21 -47 -55 -22 -109 -5.49 -60 -79 -92 -18 -23
Net Cash From Continuing Operating Activities
-21 -47 -55 -22 -109 -5.49 -60 -79 -92 -18 -23
Net Income / (Loss) Continuing Operations
-25 -57 -58 -74 -106 8.41 -88 -85 -119 -29 -18
Consolidated Net Income / (Loss)
-25 -57 -58 -74 -106 8.41 -88 -85 -119 -29 -18
Depreciation Expense
0.84 1.47 0.50 0.37 0.20 0.21 0.25 0.25 0.26 0.10 0.10
Amortization Expense
-0.02 -0.22 0.58 -1.82 -0.78 0.96 2.17 0.26 -0.40 0.00 -0.20
Non-Cash Adjustments To Reconcile Net Income
2.52 2.78 5.30 10 16 15 21 19 17 2.36 -5.69
Changes in Operating Assets and Liabilities, net
-0.13 5.88 -3.16 43 -18 -30 5.26 -13 9.36 8.64 0.51
Net Cash From Investing Activities
-92 45 -37 -83 -31 -20 -4.75 129 43 0.00 -10
Net Cash From Continuing Investing Activities
-92 45 -37 -83 -31 -20 -4.75 129 43 0.00 -10
Purchase of Investments
- -69 -127 -338 -286 -233 -209 -96 -114 0.00 -31
Sale and/or Maturity of Investments
- 114 91 255 254 213 184 224 159 0.00 21
Net Cash From Financing Activities
76 0.12 88 111 143 39 47 0.31 38 27 23
Net Cash From Continuing Financing Activities
76 0.12 88 111 143 39 47 0.31 38 27 23
Payment of Dividends
- - - - - - - - - -1.30 -2.82
Issuance of Debt
- - - - - - - - - 28 0.00
Other Financing Activities, net
0.36 0.12 1.70 19 6.11 39 47 0.31 37 0.01 26

Quarterly Cash Flow Statements for Tvardi Therapeutics

This table details how cash moves in and out of Tvardi Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-5.19 -1.63 -6.67 22 -20 -7.28 0.77 -0.68 -0.88 -4.09 6.51
Net Cash From Operating Activities
-30 24 -6.66 -4.83 -7.69 -8.87 -4.26 -5.69 -5.86 -9.23 -6.38
Net Cash From Continuing Operating Activities
-30 24 -6.66 -4.83 -7.69 -8.87 -4.26 -5.69 -5.86 -9.23 -6.38
Net Income / (Loss) Continuing Operations
-31 20 -5.51 -13 -9.58 -0.51 -5.53 -7.28 -6.80 -6.46 -6.12
Consolidated Net Income / (Loss)
-31 20 -5.51 -13 -9.58 -0.51 -5.53 -7.28 -6.80 -6.46 -6.12
Depreciation Expense
0.04 0.01 0.02 0.02 0.02 0.05 0.02 0.02 0.02 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income
7.32 -7.13 0.10 2.07 5.60 -11 0.36 0.37 0.39 0.36 0.41
Changes in Operating Assets and Liabilities, net
-6.61 11 -1.26 5.78 -3.66 2.45 0.91 1.23 0.57 -3.14 -0.69
Net Cash From Financing Activities
-0.69 0.69 -0.01 27 -1.60 22 -0.32 0.00 0.00 - 13
Net Cash From Continuing Financing Activities
-0.69 0.69 -0.01 27 -1.60 22 -0.32 0.00 0.00 - 13
Other Financing Activities, net
-0.69 0.69 - - 0.00 24 0.11 0.00 0.00 - 13

Annual Balance Sheets for Tvardi Therapeutics

This table presents Tvardi Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
111 64 97 191 233 271 247 182 126 35 32
Total Current Assets
109 61 95 168 166 195 173 169 116 32 32
Cash & Equivalents
15 12 9.39 15 18 32 13 64 52 32 21
Short-Term Investments
92 46 83 146 137 149 154 82 49 0.00 10
Prepaid Expenses
1.73 1.53 1.64 4.81 8.86 12 2.52 16 8.15 0.07 0.73
Plant, Property, & Equipment, net
1.26 1.61 1.18 0.88 0.70 0.84 0.63 0.43 3.32 0.08 0.05
Total Noncurrent Assets
0.70 0.77 0.77 22 67 75 73 13 6.36 3.43 0.48
Intangible Assets
- - - - - - - - - 0.39 0.32
Other Noncurrent Operating Assets
- - 0.77 0.41 3.44 4.69 3.38 1.55 6.36 3.04 0.16
Total Liabilities & Shareholders' Equity
111 64 97 191 233 271 247 182 126 35 32
Total Liabilities
5.85 13 10 57 46 22 20 23 69 41 11
Total Current Liabilities
5.27 12 8.51 40 43 18 18 23 26 10 11
Accounts Payable
5.27 12 8.51 14 20 17 16 22 26 2.19 3.22
Accrued Expenses
- - - - - - - - - 8.08 7.71
Other Current Liabilities
- - - - 0.97 1.60 1.76 1.92 0.00 0.10 0.12
Total Noncurrent Liabilities
0.59 1.57 1.72 17 3.35 3.67 1.92 0.00 43 30 0.09
Other Noncurrent Operating Liabilities
- - - - 3.35 3.67 1.92 0.00 43 0.20 0.09
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
105 51 87 134 187 249 228 159 57 -91 21
Total Preferred & Common Equity
105 51 87 134 187 249 228 159 57 -91 21
Total Common Equity
105 51 87 134 187 249 228 159 57 -91 21
Common Stock
210 213 307 428 587 641 709 727 742 1.11 131
Retained Earnings
-105 -162 -220 -294 -401 -392 -481 -566 -685 -92 -110
Accumulated Other Comprehensive Income / (Loss)
-0.04 0.00 -0.07 -0.11 0.17 0.07 -0.36 -1.67 -0.26 0.00 0.01

Quarterly Balance Sheets for Tvardi Therapeutics

This table presents Tvardi Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
115 90 72 51 39 44 39 26 18 24
Total Current Assets
101 81 64 48 39 43 38 25 17 23
Cash & Equivalents
63 47 49 37 34 21 21 20 16 22
Short-Term Investments
16 23 7.38 4.98 - 20 15 5.13 0.00 0.00
Prepaid Expenses
13 5.79 3.78 2.38 1.59 2.14 1.98 0.35 1.30 0.86
Plant, Property, & Equipment, net
1.38 3.55 3.49 3.42 0.00 0.07 0.06 0.04 0.04 0.03
Total Noncurrent Assets
13 5.33 5.15 0.00 0.00 0.55 0.52 0.45 0.41 0.38
Intangible Assets
- - - - - 0.35 0.34 0.31 0.29 0.28
Other Noncurrent Operating Assets
8.61 5.33 5.15 0.00 - 0.20 0.18 0.14 0.12 0.10
Total Liabilities & Shareholders' Equity
115 90 72 51 39 44 39 26 18 24
Total Liabilities
30 60 61 51 47 11 11 11 9.14 8.08
Total Current Liabilities
23 15 14 10 1.20 11 11 11 9.11 8.08
Accounts Payable
22 15 14 6.62 1.20 2.43 4.08 4.62 4.64 2.08
Accrued Expenses
- - - - - 8.14 6.85 6.52 4.35 5.89
Other Current Liabilities
0.50 0.22 0.17 3.42 - 0.11 0.11 0.12 0.12 0.12
Total Noncurrent Liabilities
6.82 45 47 41 46 0.15 0.12 0.05 0.02 0.00
Other Noncurrent Operating Liabilities
6.82 45 47 41 46 0.15 0.12 0.05 0.02 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
86 30 12 0.71 -8.07 33 28 15 8.38 15
Total Preferred & Common Equity
86 30 12 0.71 -8.07 33 28 15 8.38 15
Total Common Equity
86 30 12 0.71 -8.07 33 28 15 8.38 15
Common Stock
738 745 747 749 752 131 131 132 132 145
Retained Earnings
-652 -715 -735 -748 -761 -98 -103 -117 -124 -130
Accumulated Other Comprehensive Income / (Loss)
-0.44 -0.19 -0.12 -0.03 0.00 -0.01 0.01 0.00 0.00 0.00

Annual Metrics And Ratios for Tvardi Therapeutics

This table displays calculated financial ratios and metrics derived from Tvardi Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
27,231,583.00 27,282,863.00 32,608,485.00 39,446,757.00 46,678,977.00 49,832,104.00 53,458,679.00 53,733,607.00 54,480,704.00 54,855,514.00 9,381,344.00
DEI Adjusted Shares Outstanding
756,433.00 757,857.00 905,791.00 1,095,743.00 1,296,638.00 1,384,225.00 1,484,963.00 1,492,600.00 1,513,353.00 1,523,764.00 9,381,344.00
DEI Earnings Per Adjusted Shares Outstanding
-32.64 -75.58 -64.17 -67.55 -82.04 6.08 -59.56 -57.27 -78.31 -19.29 -1.94
Growth Metrics
- - - - - - - - - - -
Revenue Growth
19.70% -97.74% 959.30% 1,378.49% 47.64% 579.28% -82.95% 81.81% -49.92% -100.00% 0.00%
EBITDA Growth
-41.39% -132.84% -1.33% -32.49% -42.08% 108.25% -1,075.11% 1.97% -38.94% 76.27% 4.14%
EBIT Growth
-39.79% -130.19% -1.01% -27.56% -44.07% 107.20% -1,254.07% 4.05% -37.95% 76.16% 4.84%
NOPAT Growth
-39.38% -131.86% -1.86% -30.09% -44.32% 107.51% -1,162.85% 1.74% -38.80% 76.87% 4.84%
Net Income Growth
-39.14% -132.00% -1.48% -27.33% -43.72% 107.91% -1,151.62% 3.35% -38.65% 75.20% 38.04%
EPS Growth
-17.65% -110.00% 11.43% -10.75% -20.87% 107.23% -1,066.67% 3.35% -38.65% 75.20% 71.45%
Operating Cash Flow Growth
-21.74% -120.60% -15.72% 59.32% -389.78% 94.98% -995.08% -31.03% -16.95% 80.12% -28.37%
Free Cash Flow Firm Growth
-35.53% -102.28% -30.98% 76.72% -821.21% 76.00% -140.65% -29.84% 45.48% -44.30% 72.10%
Invested Capital Growth
-40.92% -276.30% 35.82% -755.24% 36.47% 92.09% -272.32% 117.50% -2,817.69% 84.16% -41.27%
Revenue Q/Q Growth
-19.38% 0.00% 0.00% 69.72% -4.89% 267.37% -81.58% 6.19% -1.21% -100.00% -100.00%
EBITDA Q/Q Growth
-27.57% -29.41% 13.50% -12.17% -7.39% 107.66% -306.39% 3.88% 0.74% 62.76% 20.01%
EBIT Q/Q Growth
-26.73% -27.58% 12.00% -9.69% -8.07% 106.61% -324.11% 4.76% 1.90% 62.59% 19.08%
NOPAT Q/Q Growth
-27.24% -27.47% 11.52% -10.58% -7.71% 106.99% -256.88% 2.47% -1.08% 62.59% 19.08%
Net Income Q/Q Growth
-27.72% -27.75% 11.82% -9.59% -8.09% 108.49% -470.82% 3.44% -1.71% 61.07% 46.35%
EPS Q/Q Growth
-20.48% -28.05% 18.78% -7.29% -3.75% 108.49% -394.92% 3.44% -1.71% 61.07% 9.94%
Operating Cash Flow Q/Q Growth
7.16% -23.51% 3.14% -138.44% -6.64% 95.38% -358.48% -39.43% 6.25% 40.65% 63.99%
Free Cash Flow Firm Q/Q Growth
13.86% -18.39% -4.91% -510.02% -4.25% 80.36% -347.63% -32.80% 51.30% -626.37% 72.39%
Invested Capital Q/Q Growth
-217.10% -729.81% -7.66% 13.00% 15.41% 29.45% -167.27% -69.35% -2,365.21% 83.70% -14.79%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 82.65% 70.56% 0.00% 0.00%
EBITDA Margin
-638.08% -65,698.84% -6,284.52% -563.16% -541.94% 6.58% -376.36% -202.93% -563.00% 0.00% 0.00%
Operating Margin
-662.32% -67,906.98% -6,529.64% -574.52% -561.60% 3.99% -386.85% -209.08% -579.43% 0.00% 0.00%
EBIT Margin
-659.66% -67,148.84% -6,402.74% -552.39% -539.02% 5.71% -386.85% -204.16% -562.33% 0.00% 0.00%
Profit (Net Income) Margin
-649.22% -66,604.65% -6,380.35% -549.51% -534.91% 6.23% -384.06% -204.16% -565.21% 0.00% 0.00%
Tax Burden Percent
98.42% 99.19% 99.65% 99.48% 99.24% 108.95% 99.28% 100.00% 100.00% 107.45% 71.79%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.51% 97.34% 94.86%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% -8.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-31.51% -73.54% -84.54% -67.16% -66.41% 3.86% -37.12% -44.25% -109.80% -114.26% -237.81%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,449.04% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-30.07% -66.10% -72.53% -51.70% -50.59% 3.06% -34.38% -39.82% -76.54% 0.00% 0.00%
Return on Assets (ROA)
-29.60% -65.57% -72.28% -51.43% -50.20% 3.34% -34.13% -39.82% -76.94% 0.00% 0.00%
Return on Common Equity (ROCE)
-31.51% -73.54% -84.54% -67.16% -66.41% 3.86% -37.12% -44.25% -109.80% 75.60% 1,089.62%
Return on Equity Simple (ROE_SIMPLE)
-23.50% -112.92% -66.98% -55.39% -56.97% 3.38% -38.87% -53.83% -207.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-18 -41 -42 -54 -78 5.87 -62 -61 -85 -20 -19
NOPAT Margin
-463.62% -47,534.88% -4,570.75% -402.16% -393.12% 4.34% -270.79% -146.36% -405.60% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.78% -19.62% -21.65% -14.40% -14.05% 1.08% -10.68% -12.29% -25.91% -18.97% 3.17%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -38.59% -148.98% 32.32% -89.39%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.36% 29.44% 0.00% 0.00%
SG&A Expenses to Revenue
204.31% 10,736.05% 1,303.18% 113.74% 89.23% 16.17% 127.71% 72.27% 132.48% 0.00% 0.00%
R&D to Revenue
558.01% 57,270.93% 5,326.45% 560.78% 572.36% 79.84% 359.13% 219.45% 517.50% 0.00% 0.00%
Operating Expenses to Revenue
762.32% 68,006.98% 6,629.64% 674.52% 661.60% 96.01% 486.85% 291.72% 649.99% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-25 -58 -58 -74 -107 7.72 -89 -85 -118 -28 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-24 -57 -57 -76 -108 8.89 -87 -85 -118 -28 -27
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.37 5.00 4.60 3.84 4.03 3.03 2.86 3.63 0.71 0.00 1.93
Price to Tangible Book Value (P/TBV)
4.37 5.00 4.60 3.84 4.03 3.03 2.86 3.63 0.71 0.00 1.96
Price to Revenue (P/Rev)
120.73 2,947.18 438.12 38.07 37.82 5.58 28.28 13.78 1.93 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 89.65 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 1.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 258.90 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
92.66 2,261.42 336.51 24.48 26.84 3.72 17.99 10.03 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 56.53 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 65.10 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 85.64 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.38 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.38 0.00
Financial Leverage
-1.03 -1.07 -1.11 -1.25 -1.25 -1.08 -1.02 -1.02 -1.20 -1.99 -2.10
Leverage Ratio
1.06 1.12 1.17 1.31 1.32 1.16 1.09 1.11 1.43 3.13 4.39
Compound Leverage Factor
1.06 1.12 1.17 1.31 1.32 1.16 1.09 1.11 1.43 3.05 4.17
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 122.85% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 122.85% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 347.14% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -369.99% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.08 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.08 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.54 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.54 0.00
Altman Z-Score
46.15 6.00 19.34 2.81 6.55 19.77 16.93 10.05 -9.33 -5.17 -4.63
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 166.16% 558.19%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
20.68 5.33 11.18 4.16 3.86 10.55 9.84 7.20 4.54 3.06 2.86
Quick Ratio
20.28 5.06 10.90 4.01 3.64 9.82 9.51 6.36 4.07 3.05 2.79
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-17 -34 -45 -10 -96 -23 -56 -72 -39 -57 -16
Operating Cash Flow to CapEx
-107,390.00% -6,608.23% -322,511.76% -30,549.32% -606,805.56% -1,572.21% 0.00% -183,093.02% -3,876.97% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -65.14 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -152.45 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -156.38 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.05 0.00 0.01 0.09 0.09 0.54 0.09 0.20 0.14 0.00 0.00
Accounts Receivable Turnover
0.00 1.03 8.68 25.68 20.97 176.81 45.51 19.88 5.93 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.93 2.37 0.00 0.00
Fixed Asset Turnover
2.27 0.06 0.65 13.10 25.17 175.43 31.31 79.22 11.19 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.39 0.26 0.00 0.00
Days Sales Outstanding (DSO)
0.00 354.39 42.07 14.21 17.41 2.06 8.02 18.36 61.59 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 124.76 153.83 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 939.40 1,393.20 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 354.39 42.07 14.21 17.41 2.06 8.02 -796.29 -1,177.78 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.40 -9.02 -5.79 -50 -31 -2.49 -9.27 1.62 -44 -6.98 -9.87
Invested Capital Turnover
-1.86 -0.02 -0.12 -0.49 -0.49 -7.96 -3.92 -10.95 -0.99 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.70 -6.62 3.23 -44 18 29 -6.78 11 -46 37 -2.88
Enterprise Value (EV)
352 194 307 330 534 502 414 420 -61 112 9.53
Market Capitalization
459 253 399 513 752 754 651 577 40 28 40
Book Value per Share
$3.86 $1.86 $2.66 $3.39 $4.00 $5.00 $4.26 $2.95 $1.05 ($1.66) $2.23
Tangible Book Value per Share
$3.86 $1.86 $2.66 $3.39 $4.00 $5.00 $4.26 $2.95 $1.05 ($1.67) $2.20
Total Capital
105 51 87 134 187 249 228 159 57 25 21
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30 0.00
Net Debt
-107 -59 -93 -183 -218 -251 -237 -157 -101 -1.36 -31
Capital Expenditures (CapEx)
0.02 0.72 0.02 0.07 0.02 0.35 -0.03 0.04 2.38 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.08 -9.06 -6.02 -34 -32 -4.34 -11 -0.36 -11 -10 -10
Debt-free Net Working Capital (DFNWC)
104 50 87 128 123 177 156 145 91 21 20
Net Working Capital (NWC)
104 50 87 128 123 177 156 145 91 21 20
Net Nonoperating Expense (NNE)
7.06 16 16 20 28 -2.54 26 24 33 9.72 -0.51
Net Nonoperating Obligations (NNO)
-107 -60 -93 -183 -218 -251 -237 -157 -101 -1.36 -31
Total Depreciation and Amortization (D&A)
0.82 1.25 1.08 -1.45 -0.58 1.17 2.42 0.51 -0.14 0.10 -0.11
Debt-free, Cash-free Net Working Capital to Revenue
-80.86% -10,539.53% -660.48% -252.82% -162.14% -3.22% -49.34% -0.85% -50.55% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
2,725.90% 58,037.21% 9,500.77% 948.04% 617.33% 130.72% 676.02% 347.41% 431.92% 0.00% 0.00%
Net Working Capital to Revenue
2,725.90% 58,037.21% 9,500.77% 948.04% 617.33% 130.72% 676.02% 347.41% 431.92% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.00) ($2.10) ($1.86) ($2.06) ($2.49) $0.18 ($1.74) ($19.08) ($26.28) ($46.59) ($2.46)
Adjusted Weighted Average Basic Shares Outstanding
27.25M 27.30M 32.69M 39.55M 46.73M 47.41M 50.72M 4.47M 4.51M 1.52M 7.42M
Adjusted Diluted Earnings per Share
($1.00) ($2.10) ($1.86) ($2.06) ($2.49) $0.18 ($1.74) ($19.08) ($26.28) ($46.59) ($3.26)
Adjusted Weighted Average Diluted Shares Outstanding
27.25M 27.30M 32.69M 39.55M 46.73M 47.92M 50.72M 4.47M 4.51M 1.52M 7.78M
Adjusted Basic & Diluted Earnings per Share
($1.00) ($2.10) ($1.86) ($2.06) ($2.49) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
24.62M 27.28M 31.20M 35.89M 42.67M 49.88M 53.51M 4.50M 4.55M 1.52M 9.38M
Normalized Net Operating Profit after Tax (NOPAT)
-18 -41 -42 -54 -78 3.77 -62 -61 -85 -20 -19
Normalized NOPAT Margin
-463.62% -47,534.88% -4,570.75% -402.16% -393.12% 2.79% -270.79% -146.36% -405.60% 0.00% 0.00%
Pre Tax Income Margin
-659.66% -67,148.84% -6,402.74% -552.39% -539.02% 5.71% -386.85% -204.16% -565.21% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -195.21 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -140.81 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -199.15 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -144.74 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.43% -15.49%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.43% -15.49%

Quarterly Metrics And Ratios for Tvardi Therapeutics

This table displays calculated financial ratios and metrics derived from Tvardi Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
54,656,413.00 54,675,954.00 54,846,639.00 54,855,514.00 4,573,606.00 9,360,904.00 9,377,433.00 9,381,344.00 9,381,344.00 9,381,344.00 13,338,943.00
DEI Adjusted Shares Outstanding
1,518,234.00 1,518,777.00 1,523,518.00 1,523,764.00 1,524,535.00 9,360,904.00 9,377,433.00 9,381,344.00 9,381,344.00 9,381,344.00 13,338,943.00
DEI Earnings Per Adjusted Shares Outstanding
-20.22 -4.59 -3.62 9.05 -6.28 0.45 -0.59 -1.27 -0.73 -0.69 -0.46
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-65.37% -100.00% -100.00% -171.07% -100.00% 0.00% 0.00% -20.33% 0.00% 0.00% 0.00%
EBITDA Growth
-9.29% 79.33% 80.47% 144.07% 66.07% 155.45% -5.08% -166.24% 28.67% -276.86% -6.15%
EBIT Growth
-7.68% 77.80% 80.36% 144.21% 65.68% 152.78% -4.62% -166.28% 28.45% -274.91% -6.57%
NOPAT Growth
-7.29% 77.80% 80.36% 163.16% 85.32% -76.44% -4.62% -146.40% -61.94% 47.68% -6.57%
Net Income Growth
-15.12% 77.84% 80.33% 142.64% 68.79% 159.74% -0.25% -186.66% 28.97% -254.96% -10.80%
EPS Growth
-15.12% 77.84% 80.33% 142.64% 68.79% 63.10% 72.43% -130.04% 80.38% 31.00% 18.64%
Operating Cash Flow Growth
12.03% 215.61% 66.12% 72.18% 74.75% -137.51% 36.03% -17.63% 23.80% -57.26% -49.89%
Free Cash Flow Firm Growth
185.11% 257.60% 341.68% -199.14% -102.27% -197.97% -194.09% 83.22% -4,949.42% 88.38% 83.84%
Invested Capital Growth
-411.46% -764.01% -2,300.87% 84.16% -5.80% 82.08% 79.93% -41.27% 75.23% 8.48% 20.65%
Revenue Q/Q Growth
-28.93% -100.00% 0.00% 0.00% 100.00% -100.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Q/Q Growth
10.94% 77.16% 15.21% 355.48% -168.57% 281.27% -260.69% -61.05% 26.17% 6.26% 4.77%
EBIT Q/Q Growth
11.94% 74.99% 20.96% 353.98% -168.35% 285.88% -256.68% -60.91% 26.21% 5.99% 4.54%
NOPAT Q/Q Growth
9.02% 75.79% 20.96% 462.83% -121.14% -431.01% 53.13% -60.91% 26.21% 5.99% 4.54%
Net Income Q/Q Growth
5.07% 77.28% 20.96% 350.08% -169.48% 184.94% -232.64% -116.18% 43.05% 5.10% 5.16%
EPS Q/Q Growth
5.07% 77.28% 20.96% 350.08% -169.48% 68.94% 41.00% -172.88% 54.66% 5.48% 30.43%
Operating Cash Flow Q/Q Growth
-75.32% 177.61% -128.16% 27.38% -59.09% -88.94% 51.98% -33.54% -3.06% -57.50% 30.85%
Free Cash Flow Firm Q/Q Growth
40.03% 46.00% -12.77% -155.59% 96.79% -7,151.71% 16.22% 90.09% -865.45% 85.51% -16.53%
Invested Capital Q/Q Growth
9.33% -12.63% 4.87% 83.70% -505.61% 80.92% -6.53% -14.79% -6.19% 29.52% 7.64%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
70.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-1,366.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-1,389.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-1,344.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-1,437.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 87.13% 100.00% 100.00% 100.00% 62.53% 100.00% 100.00% 100.00%
Interest Burden Percent
106.90% 97.13% 97.13% 109.77% 97.21% 109.95% 93.08% 199.97% 96.50% 97.41% 96.78%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-147.29% -162.68% -174.92% -114.26% -76.21% -152.43% -237.63% -237.81% -480.07% -126.19% -123.08%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-187.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-200.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-147.29% -162.68% -174.92% 75.60% -76.21% -152.43% -237.63% 1,089.62% -480.07% -126.19% -123.08%
Return on Equity Simple (ROE_SIMPLE)
-411.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-21 -5.03 -3.97 14 -3.05 -8.87 -4.16 -6.69 -4.94 -4.64 -4.43
NOPAT Margin
-972.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-10.26% -2.45% -2.42% -1.23% -12.56% 26.71% -3.43% -32.70% -6.31% -6.40% -5.77%
Return On Investment Capital (ROIC_SIMPLE)
-69.68% -43.34% -561.98% -23.68% 37.75% -26.94% -14.92% -31.93% -34.03% -55.36% -28.66%
Cost of Revenue to Revenue
29.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
319.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
1,028.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
1,460.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-29 -7.18 -5.68 14 -9.85 3.79 -5.94 -9.56 -7.05 -6.63 -6.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -6.67 -5.65 14 -9.90 3.70 -5.94 -9.57 -7.06 -6.62 -6.30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.67 1.22 23.89 0.00 0.00 6.63 13.11 1.93 2.06 2.13 1.08
Price to Tangible Book Value (P/TBV)
1.67 1.22 23.89 0.00 0.00 6.70 13.28 1.96 2.10 2.20 1.10
Price to Revenue (P/Rev)
2.94 1.41 3.29 0.00 0.00 28.85 48.27 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 23.43 43.45 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 -5.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 -5.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.16 -1.32 -1.47 -1.99 -4.79 -2.19 -2.80 -2.10 -9.20 -1.37 -1.36
Leverage Ratio
1.46 1.72 1.93 3.13 5.94 2.61 3.16 4.39 10.07 1.48 1.44
Compound Leverage Factor
1.56 1.67 1.87 3.44 5.77 2.87 2.94 8.78 9.72 1.44 1.40
Debt to Total Capital
0.00% 0.00% 0.00% 122.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 122.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 347.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% -369.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 -1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 -1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 -1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 -1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-10.60 -13.43 -19.58 -1.18 -26.77 10.33 16.49 -2.86 -5.02 -9.42 -6.61
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 166.16% 0.00% 0.00% 0.00% 558.19% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.38 4.59 4.77 3.06 32.48 4.04 3.48 2.86 2.25 1.87 2.86
Quick Ratio
4.77 4.15 4.32 3.05 30.40 3.84 3.30 2.79 2.22 1.73 2.76
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
32 47 41 -23 -0.73 -46 -38 -3.81 -37 -5.32 -6.20
Operating Cash Flow to CapEx
-3,642.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
16.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-15.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-15.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.14 0.10 0.06 0.00 0.00 0.13 0.17 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
3.86 1.72 1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
1.34 1.10 0.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
8.65 5.27 2.14 0.00 0.00 4.26 4.35 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.28 0.15 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
94.65 212.82 227.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
271.58 331.72 578.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,306.54 2,502.86 4,310.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
-940.31 -1,958.32 -3,505.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-40 -45 -43 -6.98 -42 -8.07 -8.59 -9.87 -10 -7.38 -6.82
Invested Capital Turnover
-1.25 -0.52 -0.25 0.00 0.00 -0.29 -0.29 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-53 -52 -45 37 -2.32 37 34 -2.88 32 0.68 1.78
Enterprise Value (EV)
-20 -43 -27 112 -11 177 329 9.53 4.85 2.06 -5.60
Market Capitalization
50 14 17 28 23 218 365 40 30 18 17
Book Value per Share
$0.55 $0.21 $0.01 ($1.66) ($1.77) $3.52 $2.97 $2.23 $1.55 $0.89 $1.16
Tangible Book Value per Share
$0.55 $0.21 $0.01 ($1.67) ($1.77) $3.48 $2.94 $2.20 $1.51 $0.86 $1.14
Total Capital
30 12 0.71 25 -8.07 33 28 21 15 8.38 15
Total Debt
0.00 0.00 0.00 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-70 -57 -44 -1.36 -34 -41 -36 -31 -25 -16 -22
Capital Expenditures (CapEx)
0.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.64 -6.66 -5.66 -10 3.53 -8.54 -9.06 -10 -11 -7.81 -7.22
Debt-free Net Working Capital (DFNWC)
66 50 38 21 38 32 27 20 14 7.96 15
Net Working Capital (NWC)
66 50 38 21 38 32 27 20 14 7.96 15
Net Nonoperating Expense (NNE)
9.93 1.95 1.54 0.63 6.53 -13 1.37 5.26 1.87 1.82 1.69
Net Nonoperating Obligations (NNO)
-70 -57 -44 -1.36 -34 -41 -36 -31 -25 -16 -22
Total Depreciation and Amortization (D&A)
-0.47 0.52 0.02 0.02 -0.05 -0.09 -0.00 -0.01 -0.01 0.01 0.02
Debt-free, Cash-free Net Working Capital to Revenue
-21.51% -66.57% -110.20% 0.00% 0.00% -112.83% -119.63% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
390.42% 499.33% 736.97% 0.00% 0.00% 428.64% 361.95% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
390.42% 499.33% 736.97% 0.00% 0.00% 428.64% 361.95% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($20.16) ($13.32) ($8.28) $192.96 ($3.22) $0.51 ($0.59) ($1.61) ($0.73) ($0.69) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding
1.52M 1.52M 1.52M 71.51K 1.52M 8.25M 9.38M 7.42M 9.38M 9.38M 12.65M
Adjusted Diluted Earnings per Share
($20.16) ($13.32) ($8.28) $192.96 ($3.22) ($1.00) ($0.59) ($1.61) ($0.73) ($0.69) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding
1.52M 1.52M 1.52M 71.51K 1.52M 8.46M 9.38M 7.78M 9.38M 9.38M 12.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $192.96 $0.00 $0.00 $0.00 ($1.61) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.52M 1.52M 1.52M 127.05K 9.36M 9.38M 9.38M 9.38M 9.38M 13.34M 13.36M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -5.03 -3.97 10 -3.05 -6.21 -4.16 -6.69 -4.94 -4.64 -4.43
Normalized NOPAT Margin
-893.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-1,437.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-14.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-10.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-14.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-10.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% -4.43% 0.00% 0.00% 0.00% -15.49% -7.87% -1.65% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -4.43% 0.00% 0.00% 0.00% -15.49% -7.87% -1.65% 0.00%

Financials Breakdown Chart

Key Financial Trends

Tvardi Therapeutics’ latest financial statements show a development-stage biotechnology company with no revenue, ongoing research spending and a rapidly shrinking liquidity position. The company reported no revenue in the second quarter of 2026 and a net loss of $6.5 million, or $0.69 per share. Although the loss narrowed from $6.8 million in the first quarter, the company remains dependent on cash and investment proceeds to fund operations.

  • Operating expenses declined sequentially. Total operating expenses fell to $6.6 million in Q2 2026 from $7.1 million in Q1. Research and development spending declined to $4.0 million from $4.9 million, while the net loss improved modestly.
  • The balance sheet has no reported long-term debt. Total liabilities were $9.1 million at June 30, 2026, consisting primarily of accounts payable and accrued expenses. Avoiding debt reduces interest-rate and refinancing risk.
  • Current assets exceeded current liabilities. Tvardi reported $17.1 million of current assets versus $9.1 million of current liabilities, representing a current ratio of approximately 1.9. This provides some short-term balance-sheet flexibility.
  • Investment income continues to provide limited support. Interest and investment income was $172,000 in Q2 2026, following $247,000 in Q1. While immaterial relative to operating expenses, the income helps offset a portion of the company’s research spending.
  • Cash usage remains heavily tied to clinical-development activity. Research and development represented roughly 60% of Q2 operating expenses. For a biotechnology company, this spending may support future product opportunities, but the statements do not yet show revenue or a clear path to profitability.
  • Historical comparisons are affected by restatements and corporate changes. Several 2024 and 2025 statements are identified as restated, and older filings reference Cara Therapeutics rather than Tvardi Therapeutics. Investors should use caution when comparing older revenue, earnings-per-share and share-count figures with the current company.
  • Cash and investments have fallen sharply. Cash and short-term investments totaled approximately $15.8 million at June 30, 2026, down from $24.0 million at March 31 and $36.5 million at June 30, 2025. The company had no short-term investments remaining at the latest quarter-end.
  • Operating cash burn accelerated. Net cash used in operating activities increased to $9.2 million in Q2 from $5.9 million in Q1. This was the largest quarterly operating cash outflow in the provided 2025–2026 period.
  • Liquidity may support only a limited period of operations at the current burn rate. Dividing the $15.8 million cash balance by the Q2 operating burn suggests less than two quarters of cash coverage before considering changes in spending, investment proceeds or new financing. This is a rough estimate, not company guidance.
  • Accumulated losses continue to erode shareholder equity. Retained earnings were negative $123.7 million at June 30, 2026, and total equity declined to $8.4 million from $14.5 million at the end of Q1. Continued losses could increase the likelihood of future equity financing and shareholder dilution.

Overall, the latest quarter offers modest operational positives through lower research spending and a narrower net loss, but these improvements were outweighed by substantial cash consumption. The key issues for investors are whether Tvardi can control its quarterly burn rate, generate meaningful clinical or commercial progress, and secure additional funding without materially diluting existing shareholders.

11/17/26 08:24 PM ETAI Generated. May Contain Errors.

Tvardi Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tvardi Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Below is a breakdown of Tvardi Therapeutics' net income over the past 5 years:
  • 2021: -$88.44 million
  • 2022: -$85.47 million
  • 2023: -$118.51 million
  • 2024: -$29.40 million
  • 2025: -$18.21 million
Check out Tvardi Therapeutics' forecast to explore projected trends and price targets.

Tvardi Therapeutics' total operating income in 2025 was -$26.75 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $26.75 million

Over the last 10 years, Tvardi Therapeutics' total revenue changed from $3.80 million in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Tvardi Therapeutics' cash and equivalents has ranged from $15.77 million in Q2 2026 to $62.88 million in Q3 2023, and is currently $22.28 million as of their latest financial filing in Q3 2026.

Tvardi Therapeutics had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2015.

Over the last 10 years, Tvardi Therapeutics' book value per share changed from 3.86 in 2015 to 2.23 in 2025, a change of -42.1%.



Financial statements for NASDAQ:TVRD last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners